PL2056842T3 - Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych - Google Patents

Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych

Info

Publication number
PL2056842T3
PL2056842T3 PL07760333T PL07760333T PL2056842T3 PL 2056842 T3 PL2056842 T3 PL 2056842T3 PL 07760333 T PL07760333 T PL 07760333T PL 07760333 T PL07760333 T PL 07760333T PL 2056842 T3 PL2056842 T3 PL 2056842T3
Authority
PL
Poland
Prior art keywords
modified
treatment
cancerous diseases
galactosyl ceramide
galactosyl
Prior art date
Application number
PL07760333T
Other languages
English (en)
Inventor
Paul B Savage
Luc Teyton
Albert Bendelac
Original Assignee
Scripps Research Inst
Univ Brigham Young
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Univ Brigham Young, Univ Chicago filed Critical Scripps Research Inst
Publication of PL2056842T3 publication Critical patent/PL2056842T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/06—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL07760333T 2006-04-07 2007-04-09 Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych PL2056842T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79009606P 2006-04-07 2006-04-07
PCT/US2007/066250 WO2007118234A2 (en) 2006-04-07 2007-04-09 Modified -galactosyl ceramides for staining and stimulating natural killer t cells
EP07760333A EP2056842B1 (en) 2006-04-07 2007-04-09 Modified-galactosyl ceramide for the treatment of cancerous diseases

Publications (1)

Publication Number Publication Date
PL2056842T3 true PL2056842T3 (pl) 2013-03-29

Family

ID=38581864

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07760333T PL2056842T3 (pl) 2006-04-07 2007-04-09 Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych

Country Status (12)

Country Link
US (2) US8227581B2 (pl)
EP (1) EP2056842B1 (pl)
AU (1) AU2007234753B2 (pl)
BR (1) BRPI0710668A2 (pl)
CA (1) CA2661789C (pl)
DK (1) DK2056842T3 (pl)
ES (1) ES2397975T3 (pl)
PL (1) PL2056842T3 (pl)
PT (1) PT2056842E (pl)
SI (1) SI2056842T1 (pl)
WO (1) WO2007118234A2 (pl)
ZA (1) ZA200900905B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
PT1848813E (pt) 2005-01-28 2013-07-15 Scripps Research Inst Activação de glicolípidos bacterianos de células nkt restritas ao cd1d
EP2040541B1 (en) 2006-06-30 2016-03-23 The Scripps Research Institute Adjuvants and methods of use
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
AU2013202865B2 (en) * 2007-11-07 2015-03-19 Abivax Increase of immune response and targeting by antigens and/or drug linkage
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
RU2537188C2 (ru) 2007-12-05 2014-12-27 Виттисель Композиции и способы для усиления имунного ответа на антигены
JP5809560B2 (ja) 2008-10-08 2015-11-11 アビヴァックス インフルエンザに対して使用するためのワクチン組成物
ES2345377B1 (es) * 2009-03-20 2011-07-21 Consejo Superior De Investigaciones Cientificas (Csis) (51%) Compuestos aminociclitoles, procedimiento de obtencion y usos.
WO2011112889A2 (en) 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services β-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY
EP2842961B1 (en) 2012-04-26 2016-12-14 Riken New carbamate glycolipid and use thereof
US9321796B2 (en) 2012-06-28 2016-04-26 Universiteit Gent Galactopyranosyl derivatives useful as medicaments
EP2727929A1 (en) * 2012-10-30 2014-05-07 Wittycell Method of preparation of alpha galactosyl ceramides compounds
US20170029454A1 (en) * 2013-06-28 2017-02-02 The Scripps Research Institute Nkt cell ligands and methods of use
WO2015187040A1 (en) * 2014-06-05 2015-12-10 Regan James Anderson Amino sphingoglycolipid analogues
ES2999021T3 (en) 2016-09-14 2025-02-24 Abivax Combinations including abx196 for the treatment of cancer
WO2019190986A1 (en) * 2018-03-26 2019-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 3-o-sulfo-galactosylceramide analogs as activators of type ii nkt cells and uses thereof
WO2023121483A1 (en) * 2021-12-24 2023-06-29 Victoria Link Limited Immunostimulatory compositions
CN115286667B (zh) * 2022-08-02 2024-03-26 华中农业大学 一种α-半乳糖基神经酰胺类似物及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242800A (en) 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (pl) 1992-07-16 1995-11-01 Kirin Brewery
AU683026B2 (en) 1992-10-22 1997-10-30 Kirin Pharma Kabushiki Kaisha Novel shingoglycolipid and use thereof
EP0694558B1 (en) 1993-04-15 1999-01-27 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
CZ298895A3 (en) 1993-05-14 1996-04-17 Cytel Corp Compound analogous to sialyl lex, pharmaceutical composition containing thereof and process for preparing lactosammonium salt
US6054433A (en) 1994-11-03 2000-04-25 The Regents Of The University Of California Methods and compositions for stimulating tissue growth and epithelial moisturization
US5785975A (en) 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
US6417167B1 (en) 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
CA2280130C (en) 1997-02-05 2007-12-18 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing sphingoglycolipid and process for preparing them
JP3495740B2 (ja) 1997-04-10 2004-02-09 麒麟麦酒株式会社 α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤
US6492337B1 (en) 1997-12-30 2002-12-10 A+ Science Ab Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complication
DE69943314D1 (de) 1998-02-12 2011-05-12 Kapil N Bhalla Sphingolipid-derivate und verfahren zu deren verwendung
US20030157113A1 (en) * 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
AU2001252599A1 (en) 2000-04-28 2001-11-12 Orient Cancer Therapy Co., Ltd. Remedies for cancer
JP4410913B2 (ja) 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
WO2001098317A2 (en) 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
AR034413A1 (es) 2000-08-25 2004-02-25 Nestor Abel Chamoles Metodo para determinar la actividad de las enzimas lisosomales
EP1434859A2 (en) 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
KR20050043736A (ko) 2001-11-06 2005-05-11 오리엔트 캔서 세라피 컴퍼니 리미티드 항암 조성물
US7273853B2 (en) 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
AU2003251518B2 (en) 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
US7645873B2 (en) * 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
AU2003225891A1 (en) * 2003-03-20 2004-11-19 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
CA2560969A1 (en) 2004-03-31 2005-11-03 New York University Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
EP1784196B1 (en) 2004-08-27 2016-12-21 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
CA2578052C (en) 2004-09-03 2013-08-13 The University Of Chicago Methods of activating nkt cells
US7534434B2 (en) 2004-12-28 2009-05-19 The Rockefeller University Glycolipids and analogues thereof as antigens for NK T cells
PT1848813E (pt) 2005-01-28 2013-07-15 Scripps Research Inst Activação de glicolípidos bacterianos de células nkt restritas ao cd1d
KR100764678B1 (ko) 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
BRPI0617687A2 (pt) 2005-10-25 2011-08-02 Ludwig Inst Cancer Res composto, método para proteger um indivìduo mamìfero contra, ou tratar, um vìrus, infecção microbiana, parasita, uma doença auto-imune, cáncer, alergia ou asma, e, composição farmacêutica
EP2040541B1 (en) 2006-06-30 2016-03-23 The Scripps Research Institute Adjuvants and methods of use
EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells

Also Published As

Publication number Publication date
CA2661789A1 (en) 2007-10-18
ZA200900905B (en) 2010-06-30
AU2007234753B2 (en) 2013-02-21
PT2056842E (pt) 2013-01-24
US20090047299A1 (en) 2009-02-19
CA2661789C (en) 2014-06-03
WO2007118234A2 (en) 2007-10-18
SI2056842T1 (sl) 2013-02-28
US20120270815A1 (en) 2012-10-25
WO2007118234A3 (en) 2007-12-06
EP2056842A4 (en) 2010-10-06
EP2056842B1 (en) 2012-10-17
DK2056842T3 (da) 2013-01-14
ES2397975T3 (es) 2013-03-12
BRPI0710668A2 (pt) 2011-08-16
AU2007234753A1 (en) 2007-10-18
US8765692B2 (en) 2014-07-01
US8227581B2 (en) 2012-07-24
EP2056842A2 (en) 2009-05-13

Similar Documents

Publication Publication Date Title
SI2056842T1 (sl) Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
ZA201001304B (en) Compositions for the treatment of neoplastic diseases
IL248204A0 (en) Combined treatment of tumors expressing 38cd
IL194076A0 (en) Imidazolothiazole compounds for the treatment of disease
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
IL193747A0 (en) New therapeutic combinations for the treatment of depression
GB0602178D0 (en) Therapeutic treatment
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
EP2004204A4 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
ZA200806808B (en) Treatment of stressed patients
EP2320939A4 (en) TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
GB0909297D0 (en) Composition for the treatment of skin conditions
PL2076268T3 (pl) Roskowityna do leczenia pewnych chorób torbielowatych
IL213703A (en) Compounds for the treatment of pain and other diseases
GB0608655D0 (en) Therapeutic Treatment
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
GB0610183D0 (en) Treatment of neurodegenerative diseases
GB0610909D0 (en) Therapeutic treatment
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
EP2059238A4 (en) THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS
EP1846013A4 (en) TREATMENT OF SKIN DISEASES
GB0623740D0 (en) Treatment of disease